



# SAFETY AND EFFICACY OF A NOVEL SELECTIVE GROWTH FACTOR PRODUCT IN A SILICONE CREAM MATRIX FOR POST MICRONEEDLING PROCEDURES

## Background

**Skinuva® Scar** is a silicone cream matrix that incorporates novel selective Growth Factors, Hyaluronic Acid, Vitamin C, Aloe Vera, and Centella Asiatica. In a recent multicenter, head-to-head study, it was shown to be safe and more effective than silicone cream in the healing of post-procedural scars. **We hypothesized that the use of Skinuva® Scar in microneedling patients will be safe and effective for healing.**



## Study Design/Materials and Methods

We performed **platelet rich plasma (PRP) and microneedling treatments** resurfacing for the full face on 15 patients (13 female; 2 male). Patients were an average age of 47.4 years (standard deviation (SD) +/- 13.5 years). **All were instructed to use Skinuva® Scar immediately post-treatment up to 6 times per day for the full face for one week.** Physician assessments of healing were performed on day 3 and day 7. Erythema, edema, crusting, and exudation were assessed at both visits on a scale of 0, being not present, to 4, being severely present. A patient assessment of the tolerability of Skinuva® Scar was assessed at day 7 and graded on a scale of 0, being completely tolerable, to 4, being intolerable.

## Results

On day 3, for the physician assessment the average grade for erythema was 1.7 (SD +/- 0.5), edema was 1.4 (SD +/- 0.8), crusting was 0.28 (SD +/- .5), and exudation was 0.14 (SD +/- 0.4). On day 7, the average grade for erythema was 0.14 (SD +/- 0.4), edema was 0.21 (SD +/- 0.4), crusting was 0 (SD +/- 0), and exudation was 0 (SD +/- 0). Patients reported an average tolerability of 0.21 (SD +/- 0.4). **No adverse healing events were reported by patients in this study.**

## Conclusion

All patients reached or reported a 0 or 1 grade in all categories (erythema, edema, exudation, tolerability) at the 7 day follow-up. **Skinuva® Scar should be considered a safe and effective post-procedure product for microneedling procedures.**



*Study Performed By:*

- 1. Robin Kikuchi, BS**, Clinical Research Coordinator, Beverly Hills, CA, USA
- 2. Christopher Zoumalan, MD**, Aesthetic and Reconstructive Oculoplastic Surgery, Beverly Hills, CA, USA